FDA Committee in Favor of Imetelstat for Transfusion-Dependent MDS
The Oncologic Drug Advisory Committee voted that the benefits of imetelstat outweigh the risks for transfusion-dependent myelodysplastic syndrome and anemia.
Cancer in Bloodstream May Predict CRC Outcomes
Circulating tumor DNA-based minimal residual disease lent insight into which patients with stage 2/3 colorectal cancer may be at higher risk for recurrence and which could benefit from postsurgical chemotherapy.